Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Buy
51
GOVX Quote, Financials, Valuation and Earnings
Last price:
$2.27
Seasonality move
:
-5.75%
Day range:
$2.15 - $2.28
52-week range:
$1.09 - $11.18
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
2.51x
Volume:
382K
Avg. volume:
1.6M
1-year change:
-58.72%
Market cap:
$21.3M
Revenue:
--
EPS (TTM):
-$9.24
Analysts' Opinion
-
Consensus RatingGeovax Labs has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $14.60, Geovax Labs has an estimated upside of 546.02% from its current price of $2.26.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $8.00 representing 100% downside risk from its current price of $2.26.
Fair Value
-
According to the consensus of 3 analysts, Geovax Labs has 546.02% upside to fair value with a price target of $14.60 per share.
GOVX vs. S&P 500
-
Over the past 5 trading days, Geovax Labs has underperformed the S&P 500 by -3.29% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Geovax Labs does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Geovax Labs revenues have been falling on a year-over-year basis for 6 quarters in a row. In the most recent quarter Geovax Labs reported revenues of $2.8M.
Earnings Growth
-
Geovax Labs has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Geovax Labs reported earnings per share of -$0.91.
Enterprise value:
12.7M
EV / Invested capital:
1.50x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-0.04x
EV / Free cash flow:
-0.47x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-276.08%
Net Income Margin (TTM):
--
Return On Equity:
-575.49%
Return On Invested Capital:
-571.64%
Operating Margin:
-209.88%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | $2.8M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$22.4M | -$24.4M | -$24.5M | -$8.6M | -$5.9M | |
| EBITDA | -$22.3M | -$23.9M | -$25M | -$8.4M | -$5.8M | |
| Diluted EPS | -$43.95 | -$13.91 | -$9.24 | -$4.75 | -$0.91 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $11.7M | $18.2M | $36.1M | $14.8M | $10.9M | |
| Total Assets | $11.8M | $18.3M | $38.6M | $16.2M | $11.1M | |
| Current Liabilities | $923.7K | $335.7K | $4.8M | $7.1M | $2.6M | |
| Total Liabilities | $942.2K | $335.7K | $6.8M | $7.1M | $2.6M | |
| Total Equity | $10.8M | $18M | $31.8M | $9.1M | $8.5M | |
| Total Debt | $201.1K | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$18.6M | -$22M | -$27.2M | -$5.1M | -$9.3M | |
| Cash From Investing | -$134.3K | -- | -- | -$6.2K | -$20.7K | |
| Cash From Financing | $35.4M | -- | -- | -- | $16.3M | |
| Free Cash Flow | -$18.8M | -$22M | -$27.2M | -$5.1M | -$9.3M | |
GOVX
Sector
Market Cap
$21.3M
$46.1M
Price % of 52-Week High
20.22%
46.02%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
-58.72%
-30.52%
Beta (5-Year)
3.242
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$2.28
200-day SMA
Sell
Level
$2.45
Bollinger Bands (100)
Sell
Level
1.55 - 4.23
Chaikin Money Flow
Sell
Level
-684.4M
20-day SMA
Sell
Level
$2.40
Relative Strength Index (RSI14)
Sell
Level
45.07
ADX Line
Sell
Level
19.93
Williams %R
Neutral
Level
-76.3636
50-day SMA
Sell
Level
$2.35
MACD (12, 26)
Sell
Level
-0.07
25-day Aroon Oscillator
Sell
Level
-76
On Balance Volume
Neutral
Level
1.3B
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (1)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax’s product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors.
Stock Forecast FAQ
In the current month, GOVX has received 3 Buy ratings 0 Hold ratings, and 0 Sell ratings. The GOVX average analyst price target in the past 3 months is $14.60.
-
Where Will Geovax Labs Stock Be In 1 Year?
According to analysts, the consensus estimate is that Geovax Labs share price will rise to $14.60 per share over the next 12 months.
-
What Do Analysts Say About Geovax Labs?
Analysts are divided on their view about Geovax Labs share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Geovax Labs is a Sell and believe this share price will drop from its current level to $8.00.
-
What Is Geovax Labs's Price Target?
The price target for Geovax Labs over the next 1-year time period is forecast to be $14.60 according to 3 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is GOVX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Geovax Labs is a Buy. 3 of 3 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of GOVX?
You can purchase shares of Geovax Labs via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Geovax Labs shares.
-
What Is The Geovax Labs Share Price Today?
Geovax Labs was last trading at $2.27 per share. This represents the most recent stock quote for Geovax Labs. Yesterday, Geovax Labs closed at $2.26 per share.
-
How To Buy Geovax Labs Stock Online?
In order to purchase Geovax Labs stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
87
PSIX alert for Dec 25
Power Solutions International [PSIX] is up 27.42% over the past day.
Buy
65
TSLL alert for Dec 25
Direxion Daily TSLA Bull 2X Shares [TSLL] is up 19.46% over the past day.
Buy
75
SMLR alert for Dec 25
Semler Scientific [SMLR] is up 15.37% over the past day.
